- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.06. | Annexin comments on acquisition and focus on ANXV in ophthalmology | - | BioStock | ||
| 13.05. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Annexin Pharmaceuticals AB | 318 | GlobeNewswire | With effect from May 14, 2024, the subscription rights in Annexin
Pharmaceuticals AB will be traded on First North Growth Market. Trading will
continue up until and including May 23, 2024.
Instrument:... ► Artikel lesen | |
| 07.05. | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.05.2024 | 285 | Xetra Newsboard | Das Instrument KT7 SE0015660287 SWEDEN BUYERSCLUB AB EQUITY wird cum Kapitalmassnahme gehandelt am 07.05.2024 und ex Kapitalmassnahme am 08.05.2024 The instrument KT7 SE0015660287 SWEDEN BUYERSCLUB... ► Artikel lesen | |
| 30.04. | ANNEXIN PHARMACEUTICALS AB: Annexin's phase II study fully recruited with positive signals | 2 | Cision News | ||
| 18.04. | ANNEXIN PHARMACEUTICALS AB: Annexin towards completion of phase II study and share issue | 1 | Cision News | ||
| 14.02. | ANNEXIN PHARMACEUTICALS AB: Strong start for Annexin in 2024 | 3 | Cision News | ||
| 22.12.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of Annexin Pharmaceuticals AB (690/23) | 295 | GlobeNewswire | Trading in Annexin Pharmaceuticals AB paid subscription shares is to cease. The
last trading day is December 27, 2023.
Short name: ANNX BTA
ISIN code: SE0021148707
Orderbook ID: 313319
This... ► Artikel lesen | |
| 29.11.23 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Annexin Pharmaceuticals AB (613/23) | 466 | GlobeNewswire | With effect from November 30, 2023, the subscription rights in Annexin
Pharmaceuticals AB will be traded on First North Growth Market. Trading will
continue up until and including December 11, 2023.... ► Artikel lesen | |
| 24.11.23 | XFRA CAPITAL ADJUSTMENT INFORMATION - 24.11.2023 | 1.097 | Xetra Newsboard | Das Instrument K6X AU0000183253 LARVOTTO RESOURCES LTD. EQUITY wird cum Kapitalmassnahme gehandelt am 24.11.2023 und ex Kapitalmassnahme am 27.11.2023 The instrument K6X AU0000183253 LARVOTTO RESOURCES... ► Artikel lesen | |
| 30.10.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 30.10.2023 | 914 | Xetra Newsboard | The following instruments on XETRA do have their first trading 30.10.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 30.10.2023
Aktien
1 SE0009664154 Annexin Pharmaceuticals... ► Artikel lesen | |
| 25.10.23 | Annexin Pharmaceuticals AB: First patient treated in the second dose group in Annexin's RVO study | 331 | PR Newswire | STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- Annexin Pharmaceuticals announces that all patients in the first dose group with the lowest dose have now completed treatment in the company's clinical... ► Artikel lesen | |
| 29.09.23 | Annexin Pharmaceuticals AB: Annexin announces success in the company's cancer initiative | 294 | PR Newswire | STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- Annexin Pharmaceuticals today announces important progress in the company's preclinical cancer research where the drug candidate ANXV has shown promising... ► Artikel lesen | |
| 11.08.23 | Annexin Pharmaceuticals AB: Promising signals of effect in Annexin's RVO-study | 1.003 | PR Newswire | STOCKHOLM, Aug. 11, 2023 /PRNewswire/ -- Annexin Pharmaceuticals AB today announces that an independent evaluation of potential signals of effect has been carried out in the company's Phase... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,195 | +2,62 % | Biotech Report: Qiagen knapp im Plus, Evotec geben ab | (shareribs.com) Frankfurt / New York 23.07.2024 - Biotech-Aktien zeigen sich im deutschen Handel schwächer. Für Evotec und Biontech geht es abwärts, Qiagen kann sich behaupten. An der Wall Street verliert... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 8,220 | +149,09 % | Pre-market Movers: Windtree Therapeutics, Carbon Revolution, BurgerFi International, Everi Holdings, Nature's Miracle Holding | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Windtree Therapeutics, Inc. (WINT) is up over 117%... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 25,010 | -11,44 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
| IMMUNOVANT | 29,100 | +4,68 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 | Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 11,550 | +10,10 % | DelveInsight Business Research, LLP: Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche | The landscape of bispecifics and trispecifics antibodies is rapidly evolving, driven by advancements in immunotherapy and targeted cancer treatments. Biotech companies are racing to develop... ► Artikel lesen | |
| EVOTEC | 8,680 | -0,23 % | Evotec Aktie: Analysten sehen Wendepunkt trotz Kursrückgang | Die Evotec-Aktie verzeichnete in den letzten Handelstagen einen deutlichen Kursrückgang und notierte zuletzt bei 8,61 Euro. Trotz des aktuellen Abwärtstrends zeigen sich Analysten für die Zukunft optimistisch.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 48,130 | +7,63 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 49,950 | +2,65 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results | Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
| KINIKSA PHARMACEUTICALS | 26,120 | +0,81 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $405 - $415 million -- Abiprubart... ► Artikel lesen | |
| CG ONCOLOGY | 33,030 | +0,12 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates | Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First Patient... ► Artikel lesen | |
| IMMUNOME | 16,510 | +2,99 % | Immunome Reports First Quarter 2024 Financial Results and Provides Business Update | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial... ► Artikel lesen | |
| DYNE THERAPEUTICS | 44,590 | +4,43 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease | WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |
ANNEXIN PHARMACEUTICALS AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +4,14 % bei einem Aktienkurs von 0,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANNEXIN PHARMACEUTICALS AB finden Sie auf Wallstreet Online.
